Editorial comment on: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Colin
C
Cooper
D051722:ADAM Proteins / Q000096:biosynthesis / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000097:blood / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis / Q000235:genetics*; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000601:surgery; D012334:RNA, Neoplasm / Q000235:genetics*
D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D012334:RNA, Neoplasm; D017430:Prostate-Specific Antigen; D051722:ADAM Proteins; C098339:ADAM9 protein, human